Novo Nordisk Pharmatech A/S products

Recombinant Insulin (also known as Insulin Human AF) is a recombinant protein consisting of human insulin crystals, a biosynthetic product created using recombinant microbial expression in yeast. As insulin binds to its receptor, it initiates intracellular signalling pathways that regulate cell growth, differentiation, survival and glucose uptake. This promotes cell culture growth and enhances protein yields by modulating transcription, DNA synthesis and replication, and stimulating protein translocation. Recombinant Insulin is used to produce monoclonal antibodies, virus vaccines, gene therapy drugs, and other innovative biologic products approved for use by regulatory bodies worldwide.

TrypsiNNex® is an innovative, animal-free recombinant porcine trypsin designed for biopharmaceutical manufacturing. This enzyme is recognized for its consistency and reliability in various production processes including cell dissociation, influenza virus production, and recombinant insulin manufacturing. Engineered to provide high purity and quality, TrypsiNNex® minimizes the risks associated with viral contamination from animal-derived materials. It is expressed in E. coli as an inactive product to prevent early degradation, ensuring a stable β-trypsin content above 70%, critical for maintaining enzymatic activity and specificity. The enzyme's autolytic pathway is carefully managed to sustain its functional form, crucial when processing precursor proteins like pro-insulin. Manufactured under GMP conditions as per IPEC guidelines, TrypsiNNex® offers high enzymatic activity and maintains stability for 36 months at -20ºC. Its formulation includes 10 mM HCl and 20 mM CaCl2, with low microbial contamination levels, making it suitable for stringent biopharma environments.